NasdaqGS:MRNABiotechs
A Look at Moderna (MRNA) Valuation After Key Oncology Trial Milestone and Recent Setbacks
Moderna (MRNA) drew attention after announcing it had dosed the first patient in a Phase 1/2 trial of mRNA-2808, its experimental T-cell engager for relapsed or refractory multiple myeloma. This development comes as investors weigh the company’s evolving strategy amid recent revenue declines and a late-stage vaccine setback.
See our latest analysis for Moderna.
Despite the buzz around its latest oncology milestone, Moderna’s short-term momentum has faded as headwinds from a failed late-stage...